At a glance
- Originator Lantern Pharma
- Class Antineoplastics; Cyclopropanes; Indenes; Sesquiterpenes; Small molecules; Spiro compounds
- Mechanism of Action Alkylating agents; DNA damage stimulants; DNA repair inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
- Preclinical B-cell lymphoma; Mantle-cell lymphoma; Sarcoma